DS-8201a in HER2-positive Gastric Cancer That Cannot Be Surgically Removed or Has Spread (DESTINY-Gastric02)

Adenocarcinoma - GEJ Clinical Trial

Official title: A Phase 2, Open-label, Single-arm Trial of Trastuzumab Deruxtecan (DS 8201a) in HER2-positive, Unresectable or Metastatic Gastric or Gastro-esophageal Junction (GEJ) Adenocarcinoma Subjects Who Have Progressed on or After a Trastuzumab-containing Regimen (DESTINY-Gastric02)

Status Completed

Clinical Trial Summary

This study will find out if trastuzumab deruxtecan is safe and works for participants with gastric or gastroesophageal junction cancer.

They must have human epidermal growth factor receptor 2 (HER2)-positive gastric or gastro-esophageal junction (GEJ) cancer:

• that cannot be removed surgically

• that has moved to other parts of the body

• that got worse during or after treatment that included trastuzumab

The study will enroll about 80 participants. Sites will be in North America and the European Union.

Clinical Trial Description

n/a

Related Conditions & MeSH terms

• Adenocarcinoma
• Adenocarcinoma - GEJ
• Adenocarcinoma Gastric Stage IV With Metastases

• NCT number: NCT04014075
• Study type: Interventional
• Source: Daiichi Sankyo
• Status: Completed
• Phase: Phase 2
• Start date: November 26, 2019
• Completion date: February 13, 2024